Cancer News and Research

Latest Cancer News and Research

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

BSD Medical Corporation (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.

18 Nov 2009

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

CEL-SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins).

18 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Several studies have shown that lipid peroxidation stimulates collagen production in fibroblasts and hepatic stellate cells (HSC), and plays an important role in the development of liver fibrosis. Hepatoprotective effects of green tea against carbon tetrachloride, cholestasis and alcohol induced liver fibrosis were reported in many studies. However, the hepatoprotective effect of green tea in dimethylnitrosamine (DMN)-induced models has not been studied.

18 Nov 2009

Tempest over new mammography guidelines affect health legislation, insurance guidelines

Newspapers across the country featured front-page follow-up stories on new mammogram recommendations today.

18 Nov 2009

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings, the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories.

18 Nov 2009

AT&T supports PADRES Contra El Cancer in campaign to raise awareness of childhood cancer

AT&T* today announced that it will launch the fourth annual campaign to raise awareness of childhood cancer and collect donations to support PADRES Contra El Cancer (PADRES), a nonprofit organization committed to improving the quality of life for Latino children who are battling the disease, beginning November 22. AT&T set a goal of raising $300,000 this year, which would mean a total donation of $1 million to PADRES since the campaign's inception in 2007.

18 Nov 2009

Roche Applied Science announces availability of new CIM-Plate 16 for their xCELLigence System

Roche Applied Science announces the availability of the new CIM-Plate 16 for their xCELLigence System for cell analysis, for use in cancer research. The 16-well culture plate features electronic sensors for the direct study of cell migration and invasion on the xCELLigence RTCA DP Instrument.

18 Nov 2009

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.

18 Nov 2009

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Power3 Medical Products launches Phase II trials for Alzheimer's and Parkinson's diseases blood diagnostic tests

BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on Power3 Medical Products, the developer of several blood tests designed for early detection, monitoring and targeting of diseases like Alzheimer's, Parkinson's and breast cancer.

18 Nov 2009

IBM scientists work with Rizzoli Orthopedic Institute to use BioMIMS to treat genetic skeletal diseases

IBM ( IBM) announced today that its Research scientists are working with the Rizzoli Orthopedic Institute, in Bologna, Italy, to use information technology to better address treatment and research for rare genetic skeletal diseases.

18 Nov 2009

Way to capture tumor cells in the bloodstream discovered

A team led by University of Arkansas for Medical Sciences (UAMS) researchers on the cutting edge of nanotechnology has found a way to capture tumor cells in the bloodstream that could dramatically improve earlier cancer diagnosis and prevent deadly metastasis.

18 Nov 2009

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

18 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

Researchers identify new way to capture tumor cells in bloodstream; findings can improve early cancer diagnosis

Jin-Woo Kim, a biomedical engineering researcher at the University of Arkansas, is part of a cutting-edge nanotechnology research group that has discovered a way to capture tumor cells in the bloodstream. The work could dramatically improve early cancer diagnosis and prevent deadly metastasis.

18 Nov 2009

Phase 2/3 study results of Genzyme's APB announced

Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate).

18 Nov 2009

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ Chikungunya virus DNA vaccine induced protective neutralizing antibody responses in a preclinical non-human primate model.

18 Nov 2009

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information.

18 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Tempest over new mammography guidelines affect health legislation, insurance guidelines

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

AT&T supports PADRES Contra El Cancer in campaign to raise awareness of childhood cancer

Roche Applied Science announces availability of new CIM-Plate 16 for their xCELLigence System

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Power3 Medical Products launches Phase II trials for Alzheimer's and Parkinson's diseases blood diagnostic tests

IBM scientists work with Rizzoli Orthopedic Institute to use BioMIMS to treat genetic skeletal diseases

Way to capture tumor cells in the bloodstream discovered

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Researchers identify new way to capture tumor cells in bloodstream; findings can improve early cancer diagnosis

Phase 2/3 study results of Genzyme's APB announced

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

Cancer Research - Second Edition eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in